SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rudy Saucillo who wrote (1265)3/10/1998 7:50:00 PM
From: D.Right  Read Replies (1) of 2173
 
Dear Rudy:

As you only do it for fun and I am a shareholder since 1995, I think I must have read the Aug. news release many more times than you did. The 0.4% reduction of HbA1c is for type I patients with 8% or higher HbA1c entering the trial regardless the insulin dosage used. It is from 144 out of 221 patients, about 66% of the whole patient population. That is good enough for both US and European approval if confirmed by upcoming trials. As a matter of fact, I think the biggest mistake the company made was not for failing to control insulin dosage in last trial IIIs (sometimes you can not forecast everything), it was their decision to prolong the US type I trial to 12 months instead of 6 months. To get the drug to the market first and money coming to support further testing should have been their number one choice. It is too late for that now as the type I trial has been changed once and you can not change it again. At least the European file will be earlier now.

D.Right
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News